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Background: To report the results of a subgroup analysis of a prospective phase II trial focussing on radiation
therapy and outcome in patients with extremity soft tissue sarcomas (STS).
Methods: Between 2005 and 2010, 50 patients (pts) with high risk STS (size ≥ 5 cm, deep/extracompartimental
location, grade II-III (FNCLCC)) were enrolled. The protocol comprised 4 cycles of neoadjuvant chemotherapy with
EIA (etoposide, ifosfamide and doxorubicin), definitive surgery with IOERT, postoperative EBRT and 4 adjuvant cycles
of EIA. 34 pts, who suffered from extremity tumors and received radiation therapy after limb-sparing surgery, formed
the basis of this subgroup analysis.
Results: Median follow-up from inclusion was 48 months in survivors. Margin status was R0 in 30 pts (88%) and R1 in 4
pts (12%). IOERT was performed as planned in 31 pts (91%) with a median dose of 15 Gy, a median electron energy of
6 MeV and a median cone size of 9 cm. All patients received postoperative EBRT with a median dose of 46 Gy after IOERT
or 60 Gy without IOERT. Median time from surgery to EBRT and median EBRT duration was 36 days, respectively. One
patient developed a local recurrence while 11 patients showed nodal or distant failures. The estimated 5-year rates of
local control, distant control and overall survival were 97%, 66% and 79%, respectively. Postoperative wound complications
were found in 7 pts (20%), resulting in delayed EBRT (>60 day interval) in 3 pts. Acute radiation toxicity mainly consisted
of radiation dermatitis (grade II: 24%, no grade III reactions). 4 pts developed grade I/II radiation recall dermatitis during
adjuvant chemotherapy, which resolved during the following cycles. Severe late toxicity was observed in 6 pts
(18%). Long-term limb preservation was achieved in 32 pts (94%) with good functional outcome in 81%.
Conclusion: Multimodal therapy including IOERT and postoperative EBRT resulted in excellent local control and
good overall survival in patients with high risk STS of the extremities with acceptable acute and late radiation side
effects. Limb preservation with good functional outcome was achieved in the majority of patients.
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Soft tissue sarcomas represent a rare tumor entity, ac-
counting for less than 1% of all adult malignancies [1].
The cornerstone of curative intent treatment is surgery
with negative margins. The addition of radiation therapy
has been shown to distinctly improve local control, espe-
cially in patients with close/positive margins or high
tumor grade [2], reaching 5-year local control rates of
80-90% after complete resection at least in extremity
tumors [2]. Although long term local control can be
achieved in the majority of patients, distant failure remains
an unsolved issue occurring in about half of the patients,
especially if risk factors like deep location, advanced tumor
size and high tumor grade [3,4] are present, thus limiting
5-year overall survival to approximately 50-60% [3,5,6].
Therefore strategies with neoadjuvant and/or adjuvant
chemotherapy have been investigated for high risk patients
to eliminate occult metastases and assess chemosensitivity
[7] by several investigators including our group. In 2004
we initiated a prospective one-armed clinical phase II
trial on “Neoadjuvant therapy in patients with high risk
soft tissue sarcoma” (NeoWTS trial, ClinicalTrials.gov
NCT01382030, EudraCT 2004-002501-72) to investi-
gate a multimodal approach consisting of neoadjuvant
chemotherapy with etoposide, ifosfamide and adriamy-
cin (EIA) followed by surgery, intraoperative electron
radiation therapy (IOERT), postoperative external beam
radiation therapy (EBRT) and adjuvant chemotherapy
using the same regimen in patients with high risk soft
tissue sarcoma. The main results of the trial regarding the
primary endpoint (disease-free survival) and secondary
endpoints (feasibility, response to neoadjuvant chemother-
apy, time to progression, overall survival and chemother-
apy associated toxicity) have been recently published by
Schmitt et al. [7] and regarding prediction of chemo-
sensitivity using fluorine-18-fluorodeoxyglucose positron
emission tomography (FDG-18-PET) by Dimitrakopoulou-
Strauss et al. [8]. Results regarding local control or side
effects mainly attributable to local therapy (surgery, IOERT
and postoperative EBRT) have not been addressed in detail
in the prior publications. However, these parameters can
strongly be influenced by tumor site. Whereas surgery
and radiation therapy are frequently less challenging
in extremity sarcomas, both treatment modalities are
often compromised regarding the radicality of resection
or the ability to achieve adequate target coverage dur-
ing (postoperative) radiation therapy in non-extremity
regions [9]. Consequently worse outcomes have been
described for example in patients with retroperitoneal
sarcomas [10], which showed significantly increased
rates of margin positive resections and local failures
compared to other sites. Although a similar distant
metastasis rate was found, this resulted in an inversion
of failure patterns in favor of local progression and aworse disease specific survival [10]. Local therapy asso-
ciated side effects also depend strongly on the tumor
region as they are mainly caused by directly adjacent
organs at risk. For these reasons and to simplify com-
parisons with other published trials, which frequently
report site-specific results, non-extremity tumors were
excluded from the current analysis. Here we present
the results of our prospective phase II trial focusing on
local outcome and local therapy side effects in the sub-
group of patients suffering from extremity tumors.
Methods
Between 2005 and 2010 fifty-one patients with his-
tologically proven potentially curable high risk soft-
tissue sarcomas have been included into a prospective
phase II trial on “Neoadjuvant Therapy in Patients with
High-Risk Soft Tissue Sarcoma” (NeoWTS Trial, Clinical
Trials.gov NCT01382030, EudraCT 2004-002501-72).
Details regarding the study protocol, study design, stat-
istical considerations, inclusion/exclusion criteria have
been published already elsewhere [7,8]. In brief, high
risk was defined as tumor size >5 cm, high grade (grade
II/III according to the Federation Nationales des Centres
de Lutte Contre le Cancer (FNCLCC)), deep or extracom-
partimental localisation, local relapse or inadequate previ-
ous therapy. Inadequate previous therapy was defined as
an initial, non-oncological surgical procedure on the
primary tumor. Tumors with size <5 cm after such pro-
cedures were also eligible, as per study protocol. Eligiliby
criteria further included classical soft tissue sarcoma
histology according to the world health organization
(WHO) classification of soft tissue tumors, age 18–65
years, normal liver, renal cardiac and bone marrow
function as well as Karnofsky-Index ≥ 80%. Histologies
were centrally reviewed by a reference pathologist (GM)
and graded according to the FNCLCC system. The same
pathologist graded the operative specimens for tumor
necrosis according to Salzer-Kuntschik [11]. The study
was carried out according to Good Clinical practice (GCP)
and the principles set in the Declaration of Helsinki 1964
as well as all subsequent revisions. The study protocol was
approved by the corresponding institutional ethics com-
mittee (Independent ethics committee of the medical
faculty at the University of Heidelberg) and legal author-
ities. All patients gave written informed consent to partici-
pate in the study.
Population of current analysis
Thirty-five of the enrolled patients suffered from ex-
tremity soft tissue sarcomas. Extremity tumors were
defined as tumors arising from the lower limb until the
iliac crest or from the upper limb until the outer margin
of the scapula. Patients with non-extremity.tumors or
tumors involving the inner pelvic area or the thoracic
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was further excluded because she received an amputa-
tion after neoadjuvant chemotherapy and was therefore
not scheduled for radiation therapy, leaving 34 evalu-
able patients for the current analysis.
Imaging studies
Staging prior to therapy consisted of MRI and/or CT scans
of the primary tumor region, FDG-18-PET and chest CT
to exclude distant metastases. Tumor response was graded
according to Response Evaluation Criteria in Solid Tumors
(RECIST) by a radiologist experienced in musculoskeletal
imaging. Follow up exams with MRI and/or CT scans were
scheduled for every 2 cycles of chemotherapy, preopera-
tively, postoperatively, after study completion for every
3 months for the first two years, every six months for the
following 3 years and annually thereafter.
Planned treatment
The planned treatment consisted of 4 cycles of neoad-
juvant chemotherapy using Etoposide, Ifosfamide and
Adriamycin (EIA regimen), followed by definitive surgery
with IOERT, postoperative EBRT and 4 cycles of adjuvant
chemotherapy using the same regimen. Details regarding
the chemotherapy regimen have been published already
elsewhere [7]. In case of tumor progression after 2 cycles
of neoadjuvant chemotherapy, the patient was referred to
immediate local therapy with no further chemotherapy.
Definitive surgery was planned four weeks after comple-
tion of neoadjuvant chemotherapy. IOERT and postop-
erative EBRT have not been further specified in the
study protocol. The recommended dose was calculated
for each patient under consideration of the individual
situation and nearby structures at discretion of the
treating radiation oncologist. Data regarding detailed
radiation therapy parameters including radiation related
toxicities and functional outcome were cross-checked
and completed by review of patients’ charts and radi-
ation therapy documentation.
IOERT
IOERT was performed in a dedicated surgical theatre
with an integrated Siemens Mevatron ME linear accel-
erator (Siemens, Concord, USA) capable of delivering
6–18 MeV electrons and thus covering a depth up to
6 cm. After the surgical procedure, an applicator of
appropriate size was chosen to encompass the target
area which was defined in correspondence with the treat-
ing surgeon. The applicator was manually positioned and
attached to the table. Uninvolved radiosensitive tissues like
major nerves and skin were displaced or covered by lead
shielding whenever possible. The applicator was aligned
with the linear accelerator using a laser guided air-docking
system. The IOERT dose was prescribed to 90% isodose,which covered the whole surgical tumor bed with a safety
margin of 1 cm. In case of a very large tumor bed, which
could not be covered by a single applicator, either multiple
fields were used or the intraoperative target volume was
restricted to the area at highest risk for close or positive
margins according to the treating surgeon. A dose of
15 Gy was attempted but could be reduced to 10–12 Gy
at the discretion of the treating radiation oncologist if
uninvolved radiosensitive structures at risk for severe
radiation toxicity (e.g. major nerves) could not be re-
moved from the irradiation field.
External beam radiation therapy (EBRT)
External beam radiation therapy was performed by linear
accelerators using CT-based 3D-conformal techniques in
all patients. Patients were treated using multiple field
techniques. At our institution, the target volume in-
cluded the surgical volume with a safety margin of 2 cm
in axial direction and 4 cm in longitudinal direction.
Margins could be reduced in case of anatomical borders
like uninvolved bones. The surgical scar was included
into the irradiation field and at least one third of the
circumference of the extremity was spared from irra-
diation to prevent chronic lymph edema whenever
possible. A total dose of 40–50.4 Gy was attempted after
IOERT depending on IOERT dose and resection margin
at the discretion of the treating radiation oncologist. In
patients, who did not receive an anticipated IOERT boost,
postoperative radiation therapy included an external beam
boost to the surgical bed with a margin of 1–2 cm in all
directions to a total dose of ≥ 60 Gy. Conventional frac-
tionation (single dose 1.8-2 Gy) was used in all cases.
Definition of events and statistical considerations
Local control (LC) was defined as absence of tumor
regrowth after surgery in the primary tumor region.
Distant control (DC) was defined as absence of nodal
or distant metastases. Disease-free survival (DFS) was
defined as absence of local/distant failure and death
from any cause. Overall survival (OS) was defined as
absence of death from any cause. LC, DC and DFS were
calculated from the date of definitive surgery until the
corresponding event or the last follow-up information.
OS was calculated from the first day of treatment until
death or the last follow-up information. All time to event
data was calculated using the Kaplan-Meier method.
Toxicity was scored using the Common Terminology
Criteria for Adverse Events (CTCAE) V3.0.
Results
A total of 34 patients have been included into the current
analysis. All patients received neoadjuvant chemotherapy,
definitive surgery and radiation therapy. For detailed
patient characteristics see Table 1. The median follow
Table 2 Response to neoadjuvant treatment





Tumor necrosis (Salzer-Kuntschik) N %
1 (no vital tumor) 5 15
2 (single vital tumor cells) 3 9
3 (vital tumor < 10% ) 1 3
4 (vital tumor 10-50%) 9 26
5 (vital tumor > 50%) 15 44
6 (completely vital tumor) 1 3
n: number of patients,%: percentage, RECIST: response evaluation criteria in
solid tumors, CR: complete remission, PR: partial remission, SD: stable disease,
PD: progressive disease.
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was 43 months (9–80 months) and 38 months (6–78
months) from the date of surgery. Median follow up in
survivors was 47 months from inclusion and 43 months
from surgery.
Response to neoadjuvant chemotherapy
Although at least minor tumor shrinkage was observed
in the majority of patients, according to RECIST criteria
most patients showed stable disease on imaging and
poor response (defined as > 10% vital tumor) according
to the pathological specimen. For detailed information
about response see Table 2.
Surgery
Definitive surgery was performed in all patients. Surgical
procedures consisted of attempted wide excisions in 33Table 1 Patient characteristics









Upper limb 4 12
Lower limb 30 88
Histology
Liposarcoma 10 29






FNCLCC grade 2 16 47
FNCLCC grade 3 18 53
Size at FD
5-10 cm 17 50
> 10 cm 17 50
Prior surgery
Biopsy only* 26 76
Previous surgery** 8 24
n: number of patients,%: percentage, age:[years], NOS: sarcoma not otherwise
specified, MFH: malignant fibrous histocytoma, FNCLCC: Federation Nationales
des Centres de Lutte Contre le Cancer, FD: first diagnosis, cm: centimeter, *: no
surgery except incisional biopsy for pathological diagnosis, **: non-oncological
surgical procedures.patients (97%), whereas one patient received a planned
marginal excision to prevent a major functional deficit.
Resection of the fibular nerve or its major branches was
needed in 4 patients with lower extremity sarcoma. Two
patients received an endoprothetic implant.
Negative margins (R0) were achieved in 30 patients
(88%), while microscopic positive margins (R1) were found
in 4 patients (12%). No patient had macroscopic residual
disease. The minimal surgical margins after complete
resection measured in the pathological specimen were
<0.5 cm in 17 cases, 0.5-1 cm in 6 cases, and 1–2 cm in
2 cases. In 5 patients no vital residual tumor was found.
IOERT
Intraoperative radiation therapy was performed as planned
in 31 of the 34 patients (91%). Three patients did not
receive IORT due to patient refusal or technical reasons.
IOERT was performed with a median dose of 15 Gy, a
median electron energy of 6 MeV and a median cone
size of 9 cm. For detailed IOERT characteristics see
Table 3. Major nerves had to be included in the IOERT
volume in 12 patients. In 9 of these cases, the IOERT
dose was therefore restricted to 10–12 Gy.
EBRT
All patients received EBRT postoperatively. The median
time interval between surgery and start of EBRT was
36 days (range 22–158 days) and only 3 patients started
EBRT more than 60 days after surgery. Reasons for
delayed start of EBRT were wound complications in all
of them, one therefore received postoperative CHT prior
to postoperative radiation therapy. EBRT was performed
using CT-based 3D-conformal treatment planning and
conventional fractionation in all cases. Median EBRT
dose was 46 Gy (range 20–54 Gy) in patients who had
Table 3 Radiation therapy characteristics
Radiation therapy N %
IOERT dose
10 Gy 3 10
12 Gy 8 26
15 Gy 20 65
IOERT energy
6 MeV 21 68
8 MeV 8 26




median size 9 cm
min size 5 cm
max size* 22 cm
EBRT total dose
< 40 Gy 1 3
40-50.4 Gy 29 85
> 50.4** 4 12
n: number of patients,%: percentage (IOERT n = 31, EBRT n = 34), IOERT:
Intraoperative electron radiation therapy, EBRT: external beam radiation
therapy, Gy: Gray, MeV: mega electron volts, cm: centimeter, min: minimum,
max: maximum, *: sum of multiple fields, **: one patient received two additional
fractions for compensation of a planned treatment break for a total dose of
54 Gy, three patients without IORT boost received a total dose of 60 Gy.
Time [months]












Figure 1 Local Control (dotted lines: 95% confidence interval).
Time [months]












Figure 2 Disease-free Survival (dotted lines: 95%confidence interval).
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Median duration of EBRT was 36 days (range 13–50).
EBRT was prematurely finished in one patient after
20 Gy according to patient’s choice. One patient had a
planned treatment break >3 days during external beam
radiation and received two additional fractions for com-
pensation up to a total dose of 54 Gy. For detailed radi-
ation therapy characteristics see Table 3.
Local control
Local recurrence was observed in one patient 14 months
after definitive surgery. All other patients remained lo-
cally controlled, resulting in estimated 3- and 5-year
local control rates of 97% (95%-confidence intervall:
79.2-99.5%, see Figure 1).
Disease free survival and overall survival
Distant failure was found in 11 patients after 3 to
40 months (median 9 months). In 7 patients the initial
site of failure was lung only (63%), whereas two patients
developed lung and lymph node metastases at the same
time and two patients suffered from nodal failure only.
The resulting estimated 3- and 5-year disease-free survival
rates were 72% (95%-CI: 52.2-84.2%) and 66% (95%-CI:
45.7-80.8%), respectively (see Figure 2). Three of the fourpatients with R1-resection failed distantly compared to 8
out of 30 in case of R0-resection, leading to a statistically
significant difference in distant control and disease-free
survival according to margin status (p = 0.017). Consider-
ing overall survival, we observed a total of 7 deaths, result-
ing in estimated 3- and 5-year rates of overall survival of
84% (95%-CI: 65.8%-93.1%) and 79% (95%-CI: 59.2%-
90.4%), respectively (see Figure 3). All deaths were related
to disease progression.
Time [months]












Figure 3 Overall Survival (dotted lines: 95% confidence interval).
Table 4 Severe chemotherapy associated toxicity
CHT toxicity Grade 3 Grade 4
n % n %





Neutropenic fever 2 6%
Hemolysis 1 3%
Diarrhea 1 3%
CHT: chemotherapy, n: number of patients,%: percentage, toxicity of
neoadjuvant and adjuvant cycles pooled together, some patients had more
than one toxicity.
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Postoperative wound complications were observed in 7
patients (20%). These included two patients with non-
infectious wound dehiscence (grade 1), two with seroma
formation requiring puncture or drainage (grade 2), and
three with abscess formation requiring intravenous anti-
biotics and/or re-operations (grade 3). Four patients had
nerve resections and showed corresponding deficits post-
operatively. Five additional patients had dys-/paresthesia
outside the scar region postoperatively, which resolved in
three and persisted in two patients.
Chemotherapy associated toxicity
Overall, chemotherapy was well tolerated. Severe toxicity
(defined as grade ≥ 3) was observed mainly as haemato-
logical side effects in 13 of 34 patients (38%), including
three patients with grade 4 reactions. No severe renal,
cardiac or hepatic toxicity were found. Cycle delays were
needed in four and dose reductions in two patients. For
detailed information see Table 4.
Acute toxicity during EBRT
Mild radiation dermatitis (grade 1) was observed in the
majority of patients (n = 18) during postoperative radi-
ation therapy. Eight patients (24%) developed grade 2
radiation dermatitis, but none showed grade 3 derma-
titis. Slight increases in lymph edema during adjuvant
radiotherapy were observed in 6 patients and one pa-
tient developed a venous thrombosis.
Four patients receiving postoperative chemotherapy
developed radiation recall dermatitis. Recall dermatitis
developed 14–41 days from the last day of irradiationduring the first or second cycle of adjuvant chemother-
apy after complete restitution of acute radiation induced
skin reaction. Two patients showed mild reactions (grade 1),
while 2 patients had moderate dermatitis (grade 2). Ra-
diation recall dermatitis resolved in all patients until the
following chemotherapy cycle without dose reductions.
None of the patients developed a recurrence of recall
dermatitis during the following cycles. Onset of recall
dermatitis was not correlated with the severity of skin
reaction during EBRT (none had grade 2 skin reaction).
Late toxicity
Mild to moderate late toxicities were observed in the
majority of patients, mainly as hyperpigmentation of
skin. Severe late toxicity was observed 6 patients (18%).
For detailed information see Table 5. In particular, one
patient suffered from new onset neuropathy with partial
paresis, one from deep vein thrombosis and two patients
from severe impairment of joint function. Two patients
required surgical revisions due to late toxicity, one due
to infection and dysfunction of a prosthetic implant and
one after bone necrosis with fracture.
Functional outcome
Overall functional outcome was good in the majority of
patients. At one and two years after surgery, 4 of 30
(13%) and 4 of 26 (15%) evaluable patients had severe
impairment of limb function (defined as interfering with
ADL), respectively. The cumulative incidence including
patients with shorter follow-up or improvement of func-
tion over time was 6 of 34 (18%) in the first year and 8
of 34 (23%) in 2 years from surgery, including two sec-
ondary amputations.
Secondary amputations were needed in two patients
(6%), both disease-related. One amputation was per-
formed due to a local recurrence, which has been de-
scribed above (see local control paragraph). The second
patient was a 44 year old male with a 7 cm high grade
Table 5 Late toxicity
Late toxicity All grades Grade 3
n % n %
Hyperpigmentation 20 59%
Fibrosis 10 29%
Neuropathy 4 12% 1 3%
Bone necrosis 2 6% 1 3%
Bursitis 2 6%
Infection of implant 1 3% 1 3%
Deep vein thrombosis 1 3% 1 3%
Lymph edema
At 1 year 10 33%*
At 2 years 4 15%°
Joint function
At 1 year 11 37%* 2 7%*
At 2 years 6 23%° 1 4%°
n: number of patients,%: percentage, *: of 30 evaluable patients, °: of 26
evaluable patients, some patients had more than one toxicity.
Roeder et al. BMC Cancer 2014, 14:350 Page 7 of 12
http://www.biomedcentral.com/1471-2407/14/350sarcoma (histologically not otherwise specified, FNCLCC
grade 3) at the lower lateral thigh. According to the
protocol he was scheduled for 4 cycles of neoadjuvant
chemotherapy but showed progressive disease after 2 -
cycles and went on to local therapy directly. Wide excision
with free margins was achieved including IOERT with
15 Gy using a 9 cm cone, followed by EBRT with 45 Gy.
8 months after the end of EBRT, suspicious lymph nodes
were discovered during routine follow up in the inguinal
and iliacal region. They were surgically removed and
found positive for disease while an incisional biopsy of the
primary tumor region revealed no local recurrence. Later
on, the patient developed a massive recurrence in the
nodal areas complicated by a large haematoma and was
treated with hemipelvectomy. The final pathology assess-
ment of the hemipelvectomy specimen confined the
lymph node recurrence but revealed no vital tumor in the
primary tumor region.
In summary, long term limb preservation was achieved
in 32 patients (94%) with good functional outcome (no
interference with activities of daily life) in 81% of them.
Discussion
Here we report the results of a subgroup analysis of a pro-
spective, single institution, non-randomised trial which
investigated a complex multimodal treatment approach
consisting of neoadjuvant chemotherapy followed by
surgery, intraoperative electron radiation therapy, post-
operative external beam radiotherapy and postoperative
chemotherapy in high grade soft tissue sarcoma limited
to patients suffering from extremity tumors.
Since Rosenberg et al. [12] described a similar overall
survival comparing amputation with limb sparing surgeryfollowed by radiation, the combination approach has
emerged as the standard of care in extremity sarcomas
with high risk features. Although radiation therapy results
undoubtedly in increased rates of local control [2], high
doses of ≥ 60 Gy need to be prescribed to large volumes in
many patients which can be associated with marked acute
and late toxicities and consequently result in unfavourable
functional outcomes. Intraoperative radiation therapy is a
treatment technique, which has been developed for dose
escalation in body regions, where such doses are hardly
achievable with external beam radiotherapy alone because
of adjacent organs at risk which much lower tolerance
than in extremity regions. However intraoperative radi-
ation therapy has been introduced by several groups
including ours also in the treatment of extremity tumors
[13-16] to replace the external beam boost mainly because
of its unique opportunity to guide a high single dose
directly to the high risk region for close or positive
margins under visual control during surgery. Further
advantages in comparison to an external boost include
at least theoretically smaller field sizes (because safety
margins for daily positioning errors can be omitted),
the possibility to exclude organ at risk like major nerves
or skin from the irradiation field and the reduction of
overall treatment time. Therefore a combination of
limb sparing surgery, IOERT and EBRT according to
our institutional standard was included as local therapy
component also into our prospective phase II trial.
With a completion rate of 91% of the planned IOERT
procedures and 97% of the planned EBRT procedures
we could show that this combination can be integrated
easily into a prospective trial even using a complex
multimodal treatment regimen at least in an experi-
enced tertiary reference center. Although not further
specified in the protocol, the applied doses during
IOERT and EBRT were relatively homogenous based on
our standard operating procedures for clinical routine
use. The same was true regarding compliance to the
EBRT component. Start of EBRT had to be postponed
only in 3 of 34 patients due to postoperative wound
complications in all of them and no unplanned treat-
ment breaks > 3 days were necessary.
Using this approach, we observed an excellent 5-year
local control rate of 97% and encouraging 5-year rates
of disease-free (66%) and overall survival (79%) with ac-
ceptable acute and limited late toxicity transferring into
high rates of long-term limb preservation (94%) with
good functional outcome in the majority of patients
(81%). These results seem to compare favourably with
major retrospective series using similar combinations of
intraoperative and external beam radiation therapy (see
Table 6, [13-18], which reported consistently 5-year
local control rates of 80-90%, although keeping in mind
that the percentage of incomplete resections in our trial
Table 6 Results of major IORT series
Author Year n f/u R0 (%) IORT EBRT 5-y-LC 5-y-OS LP (%) FC (%)
Edmonson [13] 2001 39 70 62 10-20 45 90* 80 95 n.r.
Azinovic [14] 2003 45 93 67 15 45-50 80* 64* 88 77
Kretzler [15] 2004 28 52 61 12-15 50 84 66 100 59
Llacer [17] 2006 79 58 42 20 (LDR) 45-50 90 69 100 n.r.
Oertel [16] 2006 128° 33 49 15 45 83 83 90 86
Alvarez [18] 2008 53 66 n.r. 7.5-12.5 n.r. 87 75 83 81
Current Study 2013 34 43 88 10-15 40-50 97 79 94 81
n: number of patients, f/u: median follow up,%: percentage, R0: rate of microscopic complete resections, IORT: intraoperative radiation therapy dose in Gy, EBRT:
external beam radiation therapy dose in Gy, 5-y-LC: estimated 5-year-local control rate in%, 5-y-OS: estimated 5-year-overall survival rate in%, LP: limb preservation
rate, FC (%): rate of excellent/good functional outcome, *: crude rates, °: excluding patients with distant metastases at time of surgery.
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This might be at least partly attributable to the use of
neoadjuvant chemotherapy, although major responses
according to RECIST criteria were rare. Further on, local
control seemed to be at least slightly improved compared
to recent series using EBRT alone (pre- or postopera-
tively), which reported consistently 5-year-LC rates of
83-93% [6,19-26] with mainly comparable R1-resection
rates (0-25%) as in our trial. This might be attributable
to the increased biological effect of the high single dose
which was guided directly to the high risk region under
visual control via IOERT, but given the limited number
of patients in our study and the lack of a control arm, it
cannot be ruled out that this difference has occurred by
selection bias or randomly.
Aside from local control, there is an ongoing debate
not only about the value of additional boosting tech-
niques like IOERT or brachytherapy, but also about the
timing of EBRT, which is driven mainly by functional
issues. In the initial report on the prospective random-
ized trial comparing preoperative and postoperative
EBRT conducted by the NCI Canada, increased rates of
wound complications but reduced rates of acute skin
toxicity were found in the preoperative arm [27]. Sub-
sequent analyses with longer follow up failed to show
significant differences in oncological endpoints, but
reported significantly lower rates of severe fibrosis and
trends for reductions of severe edema and joint stiffness
[28,29] with preoperative radiation therapy. Although
functional outcome analysis revealed no significant dif-
ferences between the treatment arms, severe fibrosis,
edema and joint stiffness were associated with lower
functionality scores in general and their onset increased
with field size [29]. Stinson et al. [30] also reported
associations between increased total dose and/or field size
with late toxicities like pain, edema, decreased muscle
strength or range of motion in postoperatively irradiated
patients.
Compared to postoperative EBRT alone, introduction
of an IOERT boost instead of the percutaneous boostphase should lead also to a reduction in field size at least
regarding the high dose areas, which may consequently
result in reduced late toxicity and improved functional
outcome. In contrast to preoperative EBRT, a markedly
increased wound complication rate compared to postop-
erative EBRT alone seems unlikely, because the skin is
excluded from the boost area. These assumptions were,
at least in part, supported by our results.
We observed a wound complication rate of 20% in
our study, which is similar to series using postoperative
EBRT alone [27,31] and compares favourably with series
using preoperative EBRT [19,27] indicating that the use
of an IOERT boost does not increase the wound com-
plication rate. Further on, the rate of acute radiation
related side effects was similar to the preoperative arm
of the NCI trial and compares favourably with series
using postoperative EBRT alone [27,31], which is prob-
ably related to the reduced EBRT doses by omitting the
external boost phase.
Interestingly, we observed 4 cases (11%) of radiation
recall dermatitis during the adjuvant chemotherapy phase.
Radiation recall dermatitis is a poorly understood acute
inflammatory skin reaction confined to previously irra-
diated areas, which occurs triggered by drugs, especially
chemotherapy agents, after prior complete restitution of
acute radiation related side effects. Although its appear-
ance has been described in association with many com-
monly used chemotherapy substances [32], only few
systematic reports have examined its incidence. Kodym
et al. [33] reported an observational study of 91 patients
who received different chemotherapy regimens after
radiation therapy for bone metastases of which 8 (9%)
developed recall dermatitis, but did not find an associ-
ation with a particular substance or substance group.
However, based on the rare available data, adriamycin
seems to be one of the substances with an increased risk
for recall dermatitis [32]. For example, Haffty et al. [34]
described recall dermatitis in 15 of 148 patients (10%)
who received mainly adriamycin based chemotherapy
after accelerated partial breast irradiation. Because to
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described in the literature triggered by ifosfamide and
only one for etoposide [32], it seems likely that the cases
in our study were elicited by adriamycin. Several authors
have recommended withdrawal, delay or dose reductions
of the triggering agent although there is limited evidence
supporting these strategies, because even re-challenge
with the same drug does not necessarily elicit a recurrent
reaction [35]. Because in our study none of the reactions
were severe, all patients were re-challenged without dose
reductions during the following cycles and none developed
a recurrence of recall dermatitis.
The overall rate of severe late toxicity found in our study
was in the range of other series (3% to >22%) reporting on
patients treated with surgery and radiation for extremity
sarcomas without IOERT [23,30] and similar to the find-
ings of a previous large retrospective analysis of our group
with IOERT [16]. Nevertheless we observed considerable
rates of fibrosis, joint stiffness and lymph edema, although
similar or even higher rates have been reported by others
using postoperative EBRT alone. For example, Davis et al.
[29] described fibrosis ≥ grade 2 in 48%, joint stiffness in
23% and edema in 23% of the patients treated with post-
operative EBRT and Alektiar et al. [31] found 39% joint
stiffness and 32% edema even using intensity-modulated
radiation therapy. However, we also found a decrease in
overall rate and severity of lymph edema and joint stiffness
over time, probably related to ongoing physical therapy as
described by others [31], which further complicates any
comparison. In this context it should be mentioned, that
IOERT volume itself was shown as the only factor signifi-
cantly associated with severe fibrosis in the study of van
Kampen et al. [36] and therefore should be restricted to
the justifiable minimum.
The same seems true for fractures and neuropathy,
which have been described as dose limiting side effects
for IOERT in other parts of the body [37]. In our study,
one patient (3%) developed a fracture, which is in the
range of reported rate (1-8%) with [14,38] or without
IOERT [31,39,40] as part of radiation therapy. However,
as fractures may occur many years after the end of radi-
ation treatment as highlighted by a large analysis from
Gortzak et al. [40], it cannot be ruled out that the frac-
ture rate is underestimated by our analysis due to the
relatively short follow up. Considering radiation related
neuropathy, we observed 4 cases in total (12%) with
severe grade in one (3%) in the study population. Again,
similar rates have been reported in reports using EBRT
alone [41]. Alektiar et al. [31] even observed a rate of
28% in total of which 5% were grade 2/3 with postopera-
tive IMRT. However, if only the 12 patients with inclu-
sion of major nerves into the IOERT field were analysed,
the neuropathy rate increased to 25% (8% severe) in our
study, which is similar to the findings of Azinovic et al.[14] using also a combination of IOERT and EBRT, thus
indicating that major nerves should be excluded from
IOERT fields whenever possible.
The role of chemotherapy in the treatment of high-
risk sarcomas with curative intent remains controversial
as several randomized trials and meta-analyses have
reported conflicting results. In the adjuvant setting, two
major phase III trials conducted by the EORTC (62771
and 62931) [42,43] have failed to show a significant
benefit for overall survival with the addition of chemo-
therapy. While the first one reported at least a signifi-
cant benefit in relapse-free survival, this result could not
be confirmed in the latter one. Further on, the observed
improvement in relapse-free survival in EORTC 62771
was based mainly on fewer local relapses in the CHT
group without a significant difference in the frequency
of distant metastasis [42]. As a consequence, local ther-
apy was intensified in the second trial and significant dif-
ferences in local and overall relapse free survival were
no longer observed [43]. Thus one may, argue that the
value of adjuvant chemotherapy could be mainly based
on counterbalancing an inadequate local therapy while
marked improvements seem unlikely in patients with
appropriate local treatment. In contrast, two randomized
trials from Italy reported significant improvements in
overall survival for the addition of adjuvant chemother-
apy [44,45]. Although comparisons between different
trials are always difficult, interestingly the 5-years overall
survival rates of the CHT arms were similar between the
EORTC (63% and 67%) and the Italian trials (66% and
70%), while the control groups showed marked differ-
ences (56% and 67% in the EORTC, 46% and 47% in the
Italian trials), indicating that the different outcome of
the control arms might have influenced the conflicting
results. However, the initial SMAC meta-analysis [46]
also reported a significant benefit for the use of peri-
operative chemotherapy in terms of local/distant failure
free interval and relapse free survival although it failed
to show a significant difference in overall survival. Inter-
estingly, patients with extremity tumors (which usually
allow higher rates of intensified local treatments com-
pared to other body regions) showed the largest benefit
from additional chemotherapy, indicating that chemo-
therapy effects seem not restricted patients with inad-
equate local therapy. An updated meta-analysis [47]
adding several trials using more potent chemotherapy
combinations confirmed the initial findings for relapse-
free survival and showed also an improvement in overall
survival, but did not include the recent negative EORTC
trial.
Neoadjuvant approaches of chemotherapy with or
without radiation therapy theoretically have several
benefits including improved resectability with better
functional outcome, histological response evaluation
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potentially occurred microscopic distant spread. Several
non-randomized trials showed high rates of histological
response [48,49] up to ~ 50%, which correlated with
outcome including overall survival [48]. Delaney et al.
[50] and Mullen et al. [51] also described excellent
results in a highly unfavourable patient group after treat-
ment with an intensified regimen of neoadjuvant che-
moradiation at Massachusetts General Hospital (MGH),
although considerable rates of toxicity were observed.
Further on, this approach resulted in significant improve-
ments in terms of local control, freedom from distant
metastases, disease-free and overall survival compared to
a historical control group treated without chemotherapy,
highly indicating that a neoadjuvant approach might be
beneficial. However, the only randomized trial comparing
additional neoadjuvant chemotherapy with local therapy
alone published by Gortzak et al. [52] in 2001 did not find
any significant difference between the chemotherapy and
the control arm. Further on, when the MGH approach
was tested in a multi-institutional setting (RTOG 9514),
toxicity was even higher and outcomes were clearly
worse than expected from the MGH experience [22],
although the results continued to compare well with
historical data given the highly unfavourable group of
patients included.
In our study using preoperative chemotherapy alone with
radiation applied intra- and postoperatively, we observed
a moderate clinical response rate, which was in the
range reported by other groups using preoperative chemo-
therapy, chemo-hyperthermia or chemoradiation (11-29%)
[22,50,53]. However, the pathological response rate (de-
fined as <10% vital cells in our study) was lower than in
many other series [22,48,50]. This might be due to the
omission of preoperatively applied radiation therapy or
the different chemotherapy schedule in our study. Never-
theless, our results compare well with many other series
regarding local control and are in the range of other trials
using more intensive neoadjuvant approaches with higher
rates of pathological response in terms of disease-free and
overall survival. Thus, local dose escalation via IOERT
seems to be able to compensate for an unfavourable re-
sponse to neoadjuvant chemotherapy at least regarding
local control and a low rate of pathological treatment
response might not necessarily result in a poor overall
outcome.
Clearly, our study has some limitations, mainly due to
the small patient number, the relatively short follow-up
and the lack of a control arm. Further on, the study was
initially designed mainly to evaluate short term effects of
neoadjuvant chemotherapy and therefore did not include
highly standardized specifications for local therapy or
assessment of late side effects. Therefore conclusions
should be drawn with caution. Nevertheless it representsprospectively collected data on the use of intraoperative
radiation therapy embedded into a multimodal treat-
ment approach, adding valuable information to the mainly
retrospective evidence regarding this particular radiation
technique.
Conclusion
In summary, our approach consisting of neoadjuvant
chemotherapy, limb sparing surgery, intraoperative and
postoperative radiation therapy and adjuvant chemo-
therapy resulted in excellent local control rates and
good disease-free and overall survival in patients with
high risk extremity sarcomas, although objective pa-
thological response rates to neoadjuvant chemotherapy
were only moderate. Inclusion of an intraoperative radi-
ation boost into this complex multimodal approach
seemed easily manageable with high rates of local treat-
ment compliance. With this approach we observed low
rates of acute and acceptable rates of late toxicities
transferring into a high limb preservation rate with good
functional outcome. However, given the limitations of
our study, the real extent of possible benefits using add-
itional boosting techniques like intraoperative radiation
therapy compared to external beam radiation alone or
neoadjuvant chemotherapy/chemoradiation compared
to upfront surgery can only be further clarified in ran-
domized trials.
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